• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Medications to Treat OCD: What Psychotherapists Need to Know
CLINICAL UPDATE

Medications to Treat OCD: What Psychotherapists Need to Know

July 3, 2023
Jessica Goren, PharmD.
From The Carlat Psychotherapy Report
Issue Links: Editorial Information

Jessica L Goren, PharmD. Instructor in Psychiatry, Cambridge Health Alliance.

Dr. Goren has no financial relationships with companies related to this material. 

Learning Objectives

After reading this article, you should be able to:

1. Identify the primary medications used for treating obsessive-compulsive disorder (OCD).

2. Understand the importance of monitoring medication progress and communicating with prescribing professionals.

3. Demonstrate an understanding of evidence-based techniques for managing symptoms and improving functioning in clients with OCD.


As a psychotherapist treating a client with obsessive-compulsive disorder (OCD), you need to know which medications are typically prescribed along with common side effects. Cognitive behavioral therapy (CBT), including exposure and response prevention, is often the first choice for treating mild OCD (National Institute for Health Care Excellence (NICE), 2005 https://www.nice.org.uk/guidance/cg31); however, medication are usually necessary, either alone or in combination with CBT.

Selective serotonin reuptake inhibitors (SSRIs) are the primary medications for OCD. Currently, the following SSRIs are approved for treating OCD in the US (Soomro, G. M., Altman, D., Rajagopal, S., & Oakley-Browne, M. (2008). Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). The Cochrane database of systematic reviews, 2008(1), CD001765. https://doi.org/10.1002/14651858.CD001765.pub3):

  • Fluoxetine (Prozac)
  • Fluvoxamine (Luvox)
  • Paroxetine (Paxil, Pexeva)
  • Sertraline (Zoloft)

Another option is clomipramine (Anafranil), a tricyclic antidepressant (TCA) with significant serotonin reuptake inhibition properties. However, due to its side effect profile, it is usually reserved for patients who have failed SSRI treatment.

It's crucial to remember that while medications can help, they rarely lead to complete remission of OCD symptoms. Most patients will not experience substantial improvement until at least four to six weeks after starting medication, and some may take up to 10 to 12 weeks (Koran LM and Simpson HB, Practice guideline for the treatment of patients with obsessive-compulsive disorder Guideline Watch March 2013).

If a patient doesn't respond to their first medication, you should ensure comorbid psychiatric illnesses are treated and consider adding CBT, switching to a different SSRI, or using clomipramine (Koran & Simpson, 2013).

For patients who have failed multiple treatments, augmentation strategies may be beneficial. These include pro-serotonergic agents (eg, buspirone, lithium); antipsychotics; and benzodiazepines. There's strong evidence for second-generation antipsychotics like aripiprazole (Abilify) or risperidone (Risperdal) as augmentation (Brakoulias, V., & Stockings, E. (2019). A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder. Expert opinion on pharmacotherapy, 20(1), 47–53. https://doi.org/10.1080/14656566.2018.1540590 ).

Although not used often, several other medications can be used for augmentation, including ondansetron (Zofran); memantine (Namenda); riluzole (Rilutek); low-dose clomipramine; lamotrigine; and mirtazapine (Remeron). For a list of medications discussed, see the table, “FDA-Approved Medications for OCD,” (below).

Nonpharmacologic treatments showing promise for OCD include neurosurgery; deep brain stimulation (DBS); electroconvulsive therapy (ECT); and transcranial magnetic stimulation (Koran, L. M., Hanna, G. L., Hollander, E., Nestadt, G., Simpson, H. B., & American Psychiatric Association (2007). Practice guideline for the treatment of patients with obsessive-compulsive disorder. The American journal of psychiatry, 164(7 Suppl), 5–53). However, these treatments are typically reserved for patients with severe, treatment-resistant OCD or those with comorbid depression. 

As a psychotherapist, it's also important to be aware of potential side effects of the medications your clients may be taking. They may be sharing more with you about these side effects than they share with their prescribers, who often schedule relatively brief “med-check” visits. SSRIs can cause mild gastrointestinal effects, anxiety, agitation, insomnia, sexual dysfunction, weight gain, and QTc prolongation. Clomipramine, on the other hand, can cause anticholinergic side effects (which include dry mouth, dry eyes, constipation, and difficulty with urination), as well as cardiac toxicity.

Supporting medication treatment as a therapist

In addition to providing therapy to target your clients’ OCD symptoms, there are various ways you can help to enhance their response to medications. 

  1. Incorporate exposure and response prevention (ERP) techniques: Since medications alone may not lead to full remission of OCD symptoms, ensure that you're incorporating ERP techniques into your therapy sessions. This can help clients build the skills necessary to manage symptoms effectively, regardless of medication status.
  2. Discuss the role of medication in treatment goals: During the goal-setting process, discuss with your clients how medication can help them achieve their therapy goals. Explain that medication can act as a tool to reduce symptoms, making it easier for them to engage in therapeutic activities and work towards their goals.
  3. Monitor progress and ask about side effects: Regularly assess your client's response to medication, including any side effects they may be experiencing. Keep track of their progress in therapy and how the medication may be impacting their ability to engage in therapeutic activities. Share this information with the prescribing professional to ensure appropriate adjustments are made to the medication regimen (Janardhan Reddy, Y. C., Sundar, A. S., Narayanaswamy, J. C., & Math, S. B. (2017). Clinical practice guidelines for Obsessive-Compulsive Disorder. Indian journal of psychiatry, 59(Suppl 1), S74–S90. https://doi.org/10.4103/0019-5545.196976).
  4. Develop a medication tracking system: Help clients create a personalized system to track their medication usage, side effects, and progress. This can include a medication log or a smartphone app, which can improve adherence and facilitate discussions about medication-related concerns during therapy sessions.
  5. Prepare for medication discontinuation: When appropriate, discuss with your clients and the prescribing professional the possibility of tapering off medication. Help clients understand the process and potential challenges, such as the risk of relapse or withdrawal symptoms, and plan for additional therapeutic support during this transition period.
  6. Promote self-care and healthy lifestyle choices: Encourage your clients to engage in self-care activities and adopt healthy habits that can support their recovery process. This may include regular exercise, maintaining a balanced diet, practicing relaxation techniques, and getting sufficient sleep.

FDA-Approved Medications for OCD

Medication (generic/brand)

Comments

Clomipramine (Anafranil)

• Tricyclic antidepressant (TCA) that is also a nonselective serotonin reuptake inhibitor (SRI)

• Limited data that suggest that it may a be more effective treatment for OCD than the selective serotonin reuptake inhibitors (SSRIs); however, it is associated with more side effects than SSRIs

• Approved for adults and children aged 10 years and older with OCD

• Can be fatal in overdose

Fluoxetine (Prozac)

• SSRI

• Because of long half-life, there is less likelihood of withdrawal effects due to missed doses

• Approved for adults and children aged seven years and older with OCD

Fluvoxamine (Luvox)

• SSRI

• Approved for adults and children aged eight and older with OCD

• Associated with many drug interactions

Paroxetine (Paxil, Pexeva)

• SSRI

• Stronger warnings against use in pregnancy*

• Approved for adults, but not approved for pediatric patients with OCD

Sertraline (Zoloft)

• SSRI

• approved for adults and children aged six years and older with OCD

*Notes on use during pregnancy: The strongest warnings are for paroxetine, which has been linked to congenital malformations (primarily cardiovascular) associated with exposure during the first trimester. 

 

 

Psychology and Social Work Clinical Update
KEYWORDS CBT medication OCD psychotherapy side effects SSRI
    Jessica Goren, PharmD.

    Mindfulness Therapy for Adult ADHD

    More from this author
    Issue Date: January 1, 2024
    SUBSCRIBE NOW
    Table Of Contents
    Social Anxiety Disorder: Diagnosis and Treatment
    Medications to Treat OCD: What Psychotherapists Need to Know
    Pharmacotherapy for Panic Disorder: What Therapists Need to Know
    Strategies for Managing Panic Disorder
    Featured Book
    • HospPsychiatry_Spiral_Binding_Sm.png

      Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

      This comprehensive guide is designed to be a valuable resource for professionals working in...
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.